Trials examine immune drug’s potential to treat different forms of vasculitis
Two new studies provide valuable insights into the treatment of different types of vasculitis, which are conditions that cause blood vessels to become inflamed. In the studies, which appear in Arthritis & Rheumatology, investigators examine whether a medication that interferes with the activity of certain immune cells may help treat the most common form of vasculitis, as well as one of the rarest forms, both of which affect the large blood vessels.
In both studies, patients were enrolled and treated with prednisone and abatacept, a drug that impacts T cells of the immune system. After 12 weeks, patients underwent a blinded randomization to abatacept or placebo, with all patients undergoing a standardized prednisone taper so that the glucocorticoid was discontinued at week 28.
Forty-one patients with newly-diagnosed or relapsing giant cell arteritis (GCA), the most common form of vasculitis completed the first trial, and 26 patients with Takayasu's arteritis (TAK), one of the rarest forms of vasculitis, completed the second.
In the GCA trial, the relapse-free survival rate at 12 months was 48% for those receiving abatacept and 31% for those receiving placebo. Also, patients taking abatacept experienced a longer median duration of remission (9.9 months) than patients taking placebo (3.9 months).
"Prednisone is effective but associated with significant potential side effects, particularly in the older population who are affected by this disease. As relapses occur frequently in GCA, this has often meant that patients require repeated courses of prednisone," said lead author Dr. Carol Langford, MD, MHS, of the Center for Vasculitis Care and Research at the Cleveland Clinic. "The results from this study are encouraging and could lead to a novel treatment option in people with GCA."
In the TAK trial, the relapse-free survival rate at 12 months was 22% for those receiving abatacept and 40% for those receiving placebo. Abatacept was not associated with a longer median duration of remission compared with placebo (5.5 months versus 5.7 months).
"This study was important in being the first international trial that compared two different treatment approaches in TAK to determine which was more effective," said Dr. Langford. "Although abatacept was not found to provide additional benefit beyond prednisone, the study was very significant in how it was conducted and what was learned. By demonstrating that comparative studies in TAK are possible, this work will advance future investigations of novel treatment approaches in people with TAK."
Dr. Langford noted that there was no difference in the frequency or severity of adverse events between the groups in either trial.
Importantly, both trials were designed to be conducted in parallel by the same investigator team using the same study protocol. "This approach was taken with the goal of exploring the similarities and differences between these two forms of large-vessel vasculitis," said Dr. Langford. "The observation of contrasting results raises intriguing questions about these diseases and highlights the importance of continued research in vasculitis."
The studies were conducted by the Vasculitis Clinical Research Consortium and funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
For more information or to obtain a PDF of any study, please contact:
Dawn Peters (US) +1 781-388-8408
Follow us on Twitter @WileyNews
Full Citations: "A Randomized, Double-Blind Trial of Abatacept (Ctla4-Ig) for the Treatment of Giant Cell Arteritis." Carol A. Langford, David Cuthbertson, Steven R. Ytterberg, Nader Khalidi, Paul A. Monach, Simon Carette, Philip Seo, Larry W. Moreland, Michael Weisman, Curry L. Koening, Antoine Sreih, Robert Spiera, Carol A. McAlear, Kenneth J. Warrington, Christian Pagnoux, Kathleen McKinnon, Lindsy J. Forbess, Gary S. Hoffman, Renée Borchin, Jeffrey P. Krischer, and Peter A. Merkel, for the Vasculitis Clinical Research Consortium. Arthritis & Rheumatology; Published Online: January 30, 2017 (DOI: 10.1002/art.40044).
URL Upon Publication: http://doi.wiley.com/10.1002/art.40044
"A Randomized, Double-Blind Trial of Abatacept (Ctla4-Ig) for the Treatment of Takayasu's Arteritis." Carol A. Langford, David Cuthbertson, Steven R. Ytterberg, Nader Khalidi, Paul A. Monach, Simon Carette, Philip Seo, Larry W. Moreland, Michael Weisman, Curry L. Koening, Antoine Sreih, Robert Spiera, Carol A. McAlear, Kenneth J. Warrington, Christian Pagnoux, Kathleen McKinnon, Lindsy J. Forbess, Gary S. Hoffman, Renée Borchin, Jeffrey P. Krischer, and Peter A. Merkel, for the Vasculitis Clinical Research Consortium. Arthritis & Rheumatology; Published Online: January 30, 2017 (DOI: 10.1002/art.40037).
URL Upon Publication: http://doi.wiley.com/10.1002/art.40037
Author Contact: Hope Buggey, of Cleveland Clinic Corporate Communications Office, at [email protected]
About the Journal
Arthritis & Rheumatology is an official journal of the American College of Rheumatology (ACR) and covers all aspects of inflammatory disease. The American College of Rheumatology (http://www.rheumatology.org) is the professional organization whose members share a dedication to healing, preventing disability, and curing the more than 100 types of arthritis and related disabling and sometimes fatal disorders of the joints, muscles, and bones. Members include practicing physicians, research scientists, nurses, physical and occupational therapists, psychologists, and social workers. The journal is published by Wiley on behalf of the ACR. For more information, please visit http://wileyonlinelibrary.com/journal/art.
Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders.